This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat the subject.

Martino, G., Centonze, D. (2012). Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders.

Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders

CENTONZE, DIEGO
2012-08-13

Abstract

This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat the subject.
TEVA PHARMACEUTICAL INDUSTRIES, LTD., ISRAEL
13-ago-2012
13-feb-2014
US20140045887 A1
Settore MED/26 - NEUROLOGIA
English
Martino, G; Centonze, D
Brevetti
Martino, G., Centonze, D. (2012). Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders.
File in questo prodotto:
File Dimensione Formato  
Brevetto US20140045887 - Laquinimod for treatment of cannabinoid receptor type 1(cb1) mediated disorders - Google Brevetti.pdf

solo utenti autorizzati

Dimensione 362.54 kB
Formato Adobe PDF
362.54 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/103440
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact